 |
 |
 |
|
|
|
 |
 |
 |
| |
Archive for the ‘Investigations’ Category
Friday, March 12th, 2010
Christiana Care Health System (CCHS) has agreed to pay the United States and the State of Delaware $3.3 Million to settle a whistleblower lawsuit that alleged that CCHS paid kickbacks to, and entered into improper self-referral relationships, with a physicians’ practice located in New Castle, Delaware.
The qui tam whistleblowers were represented by Marc S. Raspanti, Kevin E. Raphael, and Michael A. Morse, of the national whistleblower law firm of Pietragallo Gordon Alfano Bosick & Raspanti, LLP.
The “qui tam” whistleblower lawsuit alleged that during the period from January 1997 to February 2003 CCHS violated the Federal False Claims Act, Federal Anti-Kickback Statute, Federal Stark Law, the Delaware Anti-Kickback Statute, and the Delaware False Claims act by certifying, in claims submitted to Medicare and Medicaid, that CCHS was in compliance with all laws and regulations, when in fact CCHS knew, deliberately ignored, or recklessly disregarded the fact that:
(a) CCHS was paying fees to the physicians’ practice under an “evergreen” contract that was executed in 1989, which fees, in some cases, were multiples of what Medicare or Medicaid paid CCHS as reimbursement for those services, in order, as alleged, to illegally induce the physicians’ practice to make referrals to CCHS; and/or
(b) Claims that CCHS submitted to Medicare and Medicaid were not reimbursable because CCHS and the physicians’ practice had an impermissible “financial relationship” as defined in the Stark Statute.
Attorney Marc S. Raspanti praised the courageousness of the qui tam whistleblowers in stepping forward and uncovering one of the largest false claims cases ever in the State of Delaware. Raspanti added that “this is a landmark whistleblower case because it is one of the largest ever in the State of Delaware, and because it sends a strong signal to healthcare providers that kickbacks and lucrative self-referrals violate the law and will not be tolerated.”
Attorney Kevin E. Raphael also credited the successful resolution of the case to the strong partnership between the Relators and the federal and state prosecutors, including: United States Attorney David C. Weiss; Delaware Attorney General Joseph R. Biden, III; Assistant United States Attorneys Shannon T. Hanson and Seth M. Beausang; former Delaware Deputy Attorney General Daniel R. Miller; Lawrence M. Kutys, an auditor in the United States Attorney’s Office; and former Delaware HHS-OIG Special Agents Conrad J. Quarles and Edward J. McCusker.
Attorney Michael A. Morse commented that the goal of the Stark Law, Federal Anti-Kickback Statute and Delaware Anti-Kickback Statute is to ensure that a physician’s professional judgment in referring patients for health care services is not compromised by improper financial arrangements offered to that physician.
Posted in Federal False Claims Act, Healthcare, Investigations, State False Claims Acts | No Comments »
Friday, March 12th, 2010
The Houston Independent School District has agreed to relinquish millions of dollars in requests for federal funds and to pay a total of $850,000 as part of a civil settlement relating to allegations that the school district violated the False Claims Act in connection with the Federal Communications Commission (FCC) E-Rate Program, the Justice Department recently announced.
The E-Rate program, which Congress created in the Telecommunications Act of 1996, provides funding for needy schools and libraries to connect to and utilize the Internet. Under the program, which is funded by fees collected from telephone users, schools apply for funds to pay for hardware and monthly connectivity service fees. The FCC oversees the E-Rate program.
The United States contended that the Houston Independent School District provided false information to the E-Rate program and otherwise violated the program’s requirements by engaging in non-competitive bidding practices for E-Rate contracts. The United States further alleged that school district officials received gratuities from technology vendors, including trips, meals and loans.
This settlement resolves a very interesting, novel False Claims Act case involving an FCC Program that has not received much attention prior to this lawsuit. This settlement could cause additional suits to be filed against other school districts, as the public beomes more aware of schemes in impacting this Program.
Posted in Federal False Claims Act, Government Contracts, Investigations | No Comments »
Friday, November 20th, 2009
Earlier this week, the United States Department of Justice announced that it had secured $2.4 billion in settlements and judgments in cases involving fraud against the government in the fiscal year ending Sept. 30, 2009. This represents the second largest annual recovery of civil fraud claims in history, and brings total recoveries since 1986, when Congress substantially strengthened the civil False Claims Act, to more than $24 billion.
The government’s partnership with private citizens in the fight against fraud was cemented in 1986, when Congress amended the False Claims Act, the United States’ primary tool against government fraud. The amendments strengthened the act by, among other things, revising the statute’s qui tam provisions, which were intended to encourage whistleblowers to come forward with allegations of fraud. The 1986 amendments reduced the barriers to citizens suing on behalf of the government and increased the incentives to filing such suits.
Of the $2.4 billion in settlements and judgments obtained in fiscal year 2009, nearly $2 billion was recovered in lawsuits filed under the False Claims Act’s qui tam provisions. These provisions authorize private persons, known as “relators,” to file suit on behalf of the United States against those who have falsely or fraudulently claimed federal funds. Such cases run the gamut of federally funded programs, from Medicare and Medicaid to defense and other government procurement contracts, federally insured mortgage and other federal housing programs, disaster assistance loans, agricultural subsidies and more. Persons who knowingly make false claims for federal funds are liable for three times the government’s loss plus a civil penalty of $5,500 to $11,000 for each claim. Relators recover 15 to 25 percent of the proceeds of a successful suit if the United States intervenes in the qui tam action, and up to 30 percent if the United States declines and the relator pursues the action alone. In fiscal year 2009, relators were awarded $255 million. (This figure does not include relator shares awarded after Sept. 30, 2009.)
The government’s press release can be found at: http://www.justice.gov/opa/pr/2009/November/09-civ-1253.html
Posted in Federal False Claims Act, Investigations | No Comments »
Wednesday, November 4th, 2009
The United States and the Commonwealth of Virginia have intervened in a False Claims Act suit in the Western District of Virginia against the Medicaid providers Universal Health Services Inc., Keystone Marion LLC and Keystone Education and Youth Services LLC, the Justice Department announced today. They did business as the Keystone Marion Youth Center, a residential facility in Marion, Va., that receives Medicaid funds to provide psychiatric counseling and treatment for boys ages 11-17.
This False Claims Act lawsuit was filed by several former therapists who worked at the Marion residential facility. The suit alleges that defendants provided sub-standard care to adolescents in violation of federal and state Medicaid requirements, falsified records to cover up their serious violations and filed false Medicaid claims. Under the False Claims Act, a health care provider that submits false or fraudulent claims to a federal health care program is liable for three times the government’s damages, plus a civil penalty for each false claim.
For more information: http://www.justice.gov/opa/pr/2009/November/09-civ-1191.html
Posted in Federal False Claims Act, Healthcare, Investigations, State False Claims Acts | No Comments »
Wednesday, November 4th, 2009
A hospital group based in McAllen, Texas, has agreed to pay the United States $27.5 million to settle claims that it violated the False Claims Act, the Anti-Kickback Statute and the Stark Statute between 1999 and 2006, by paying illegal compensation to doctors in order to induce them to refer patients to hospitals within the group, the United States Justice Department announced today. McAllen Hospitals L.P., d/b/a/ South Texas Health System, is a subsidiary of Universal Health Services Inc., a company based in Pennsylvania that owns hospitals and other health care centers around the country.
The settlement announced today involved allegations that the defendants had entered into financial relationships with several doctors in McAllen in order to induce them to refer patients to the defendants’ hospitals. The government alleged that these payments were disguised through a series of sham contracts, including medical directorships and lease agreements. Under the Stark Statute, Medicare providers are prohibited from billing Medicare for referrals from doctors with whom the providers have a financial relationship, unless that relationship falls within certain exceptions.
The settlement resolves allegations raised against both the parent and the subsidiary in a qui tamor whistleblower lawsuit filed in 2005 by Bruce Moilan, a former employee of the defendants, United States ex rel. Moilan v. McAllen Hospitals, L.P., et al., Case No. M-05-CV-263 (S.D. Tex.).
Violations of the federal Anti-Kickback Statute, 42 U.S.C. Section 1320a-7b(b), have served as the basis for many whistleblower (or “Qui Tam”) cases under the federal False Claims Act. The Anti-Kickback Statute, and a number of similar State laws, generally prohibit anyone from offering, paying, soliciting or receiving any remuneration to induce (or reward) a referral of a person for services or items paid for by Medicare, Medicaid, another federal healthcare program. These improper payments can come in many different forms, including, but not limited to: referral fees; finder’s fees; productivity bonuses; discounted leases; discounted equipment rentals; research grants; speaker’s fees; excessive compensation; and free or discounted travel or entertainment.
For more information: http://www.justice.gov/opa/pr/2009/October/09-civ-1175.html
Posted in Federal False Claims Act, Healthcare, Investigations | No Comments »
Wednesday, November 4th, 2009
AstraZeneca PLC announced that it has reached an agreement “in principle” to pay $520 million settle an investigation by the United States Department of Justice into the company’s marketing of schizophrenia drug Seroquel.
The U.S. Attorney’s Office in Philadelphia has been leading an investigation into AstraZeneca’s marketing of Seroquel, including allegations that the company promoted the drug for uses for which is not approved by the Food and Drug Administration (FDA).
Pharmaceuticals and other drugs are highly regulated by numerous federal and state laws and regulations. Before any drug can be approved for use in the United States, it must first be approved by the Food and Drug Administration (“FDA”). The FDA determines precisely which medical conditions a drug may be used to treat. This determination is known as the drug’s “label” or “indication.” The label or indication is critical to pharmaceutical companies because federal law restricts pharmaceutical companies to marketing or promoting drugs only for the uses or indications approved by the FDA. Physicians, by contrast, generally may prescribe drugs to treat numerous medical conditions even if the drug has not been approved by the FDA to treat those conditions. This practice is known as “off-label” use of a drug because it goes beyond those uses specifically approved by the FDA.
One common scheme by pharmaceutical manufacturers has been to market or promote their drugs to physicians for an off-label or unapproved use. Although physicians may prescribe a drug for an off-label use, pharmaceutical companies violate federal law, including the False Claims Act, when they market, promote or encourage physicians to use their drugs in an off-label or non-FDA approved manner. Pharmaceutical companies that have engaged in illegal off-label marketing or promotion of their drugs have paid the Government hundreds of millions of dollars as a result of Federal False Claims Act cases, often times brought by pharmaceutical sales representatives, sales managers, compliance officers, other pharmaceutical company employees, physicians, nurses and/or employees of hospitals or physician practices.
AstraZeneca said its net profit rose 22% in the third quarter to $2.12 billion from $1.73 billion a year earlier, while revenue increased 5.4% to $8.2 billion from $7.7 billion.
For more information see: http://online.wsj.com/article/SB10001424052748703363704574503022289816510.html?mod=googlenews_wsj
Posted in Federal False Claims Act, Healthcare, Investigations, Pharmaceuticals | No Comments »
Tuesday, October 6th, 2009
The Government Accountability Office (”GAO”) recently issued a report finding widespread problems with the quality of audits conducted by the Defense Contract Audit Agency (”DCAA”). The DCAA under the Department of Defense (DOD) Comptroller plays a critical role in defense contractor oversight by providing auditing, accounting, and financial advisory services in connection with DOD and other federal agency contracts and subcontracts.
Last year, GAO found numerous problems with DCAA audit quality at three locations in California, including the failure to meet professional auditing standards. In this latest report, GAO found audit quality problems at DCAA offices nationwide, including compromise of auditor independence, insufficient audit testing, and inadequate planning and supervision. GAO found DCAA’s management environment and quality assurance structure were based on a production-oriented mission that put DCAA in the role of facilitating DOD contracting without also protecting the public interest.
To address these system-wide problems at DCAA, the GAO made a number recommendations ranging from possible Congressional action to 15 suggested changes at the DCAA that could be implemented by, or through, the Secretary of Defense.
A copy of the GAO Report, 09-468, can be viewed on the Internet at http://www.gao.gov/new.items/d09468.pdf
Posted in Defense Industry, Government Contracts, Investigations | No Comments »
Monday, October 5th, 2009
The Internal Revenue Service (”IRS”) recently reported an increase in the number of whistleblower complaints it has received under the new IRS Whistleblower Law that was enacted in 2006. The IRS Whistleblower Law enables private individuals to report: (1) underpayments of tax; and (2) persons otherwise guilty of violating the internal revenue laws. The IRS Whistleblower Law, like the False Claims Act, rewards whistleblowers who report allegations to the government. In general, a whistleblower can receive an award of between 15% to 30% of the collected proceeds (including penalties, interest, additions to tax and additional amounts).
The IRS recently reported to Congress that it received 1,246 whistleblower claims in 2008. To meet this increased volume of claims, the staff of the IRS’ Whistleblower Office grew in 2008 from 4 to 14, including 10 analysts with substantial experience in a wide variety of IRS compliance programs.
A copy of the 2009 IRS Report to Congress can be found on the Internet at http://www.irs.gov/pub/whistleblower/annual_report_to_congress_september_2009.pdf
Posted in Federal False Claims Act, Financial Industry, Investigations | No Comments »
Monday, October 5th, 2009
The United States Government has established a new website that allows citizens to track stimulus spending under the Recovery Act. This interactive website allows stimulus spending to be tracked by state and/or zip code. The website also contains links to reports by the Government Accountability Office (”GAO”), instructions for reporting fraud, as well as other resources and information about federal stimulus spending.
This interesting new Government’s website can be found on the Internet at www.recovery.gov.
Posted in Financial Industry, Government Contracts, Investigations | No Comments »
Monday, October 5th, 2009
Welcome to the False Claims Act – Whistleblowers Blog. The Federal and State Governments spend trillions of dollars each year to fund a wide variety of programs and to purchase vast amounts of goods and services. Some of the larger government programs include: Medicare, Medicaid, Department of Defense-Military Spending, the Troubled Assets Relief Program (”TARP”), Federal Emergency Management Agency (”FEMA”) Spending, Department of Education Grants; Department of Energy Grants and Mining and Gas Royalties; and General Services Administration (”GSA”) Spending.
Each of these government programs is a frequent target for fraudulent schemes and false claims. The Government does not have the resources necessary to protect every dollar of taxpayer spending. The Government has come to rely upon Whistleblowers, often referred to as “Qui Tam Relators,” to blow-the-whistle on businesses and individuals who attempt to defraud the Government.
This blog is devoted to providing information and resources to those interested in: whistleblowers; fraud by government contractors; the Federal False Claims Act; State False Claims Acts; Government Investigations; Qui Tam Actions; Qui Tam Relators; Pharmaceutical Industry Fraud; Defense Contracting Fraud; Healthcare Fraud; Financial Industry Fraud; Construction Industry Fraud; Energy Industry Fraud; Grant Fraud; Disaster Recovery Fraud; and Government Procurement Fraud.
We welcome you to this Blog, and hope that you find the information and resources useful and enlightening.
Posted in Construction, Defense Industry, Federal False Claims Act, Financial Industry, Government Contracts, Healthcare, Investigations, Pharmaceuticals, State False Claims Acts | No Comments »
|
|
|
|
|
|
 |
 |
|
|
 |
| |
215-320-6200 |
 |
© 2010 False Claims Act. All rights reserved. | |
 |
Attorney Advertising |
 |
The information on this site is not, nor is it intended to be, legal advice. Prior results do not guarantee a similar outcome. |
| |
|
|
 |
|
 |
|
 |